Fulcrum Selling General Administrative from 2010 to 2025
| FULC Stock | USD 3.01 0.08 2.59% |
Selling General Administrative | First Reported 2018-03-31 | Previous Quarter 8.4 M | Current Value 7.7 M | Quarterly Volatility 3.3 M |
Check Fulcrum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulcrum Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.8 M, Interest Income of 1.8 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 139, Dividend Yield of 0.0 or PTB Ratio of 1.92. Fulcrum financial statements analysis is a perfect complement when working with Fulcrum Therapeutics Valuation or Volatility modules.
Fulcrum | Selling General Administrative |
Latest Fulcrum Therapeutics' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of Fulcrum Therapeutics over the last few years. It is Fulcrum Therapeutics' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fulcrum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Fulcrum Selling General Administrative Regression Statistics
| Arithmetic Mean | 16,021,841 | |
| Geometric Mean | 10,462,374 | |
| Coefficient Of Variation | 91.55 | |
| Mean Deviation | 12,845,926 | |
| Median | 8,314,000 | |
| Standard Deviation | 14,668,199 | |
| Sample Variance | 215.2T | |
| Range | 37.2M | |
| R-Value | 0.86 | |
| Mean Square Error | 61.2T | |
| R-Squared | 0.73 | |
| Significance | 0.000022 | |
| Slope | 2,640,456 | |
| Total Sum of Squares | 3227.3T |
Fulcrum Selling General Administrative History
About Fulcrum Therapeutics Financial Statements
Fulcrum Therapeutics stakeholders use historical fundamental indicators, such as Fulcrum Therapeutics' Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Fulcrum Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fulcrum Therapeutics' assets and liabilities are reflected in the revenues and expenses on Fulcrum Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fulcrum Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 36.4 M | 27.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Fulcrum Therapeutics Correlation against competitors. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.16) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.